Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06723171Phase 2Suspended

Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis

Role: lead

NCT02991651Phase 1Terminated

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

Role: lead

NCT01540071Phase 2Completed

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Role: lead

NCT02749708Phase 1Terminated

Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Role: collaborator

NCT02438215Phase 1Completed

Study of IRX4204 for Treatment of Early Parkinson's Disease

Role: lead

All 5 trials loaded